Urticaria, angioedema and dyspnoea in adjuvant therapy of melanoma with interferon alpha-2b.
Doris
D
Helbig
Jan-Christoph
JC
Simon
Regina
R
Treudler
D000799:Angioedema / Q000139:chemically induced* / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant; D004115:Dimethindene / Q000008:administration & dosage; D004342:Drug Hypersensitivity / Q000188:drug therapy / Q000209:etiology*; D004417:Dyspnea / Q000139:chemically induced* / Q000188:drug therapy; D005938:Glucocorticoids / Q000008:administration & dosage; D006634:Histamine H1 Antagonists / Q000008:administration & dosage; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D014581:Urticaria / Q000139:chemically induced* / Q000188:drug therapy
D000970:Antineoplastic Agents; D005938:Glucocorticoids; D006634:Histamine H1 Antagonists; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D004115:Dimethindene; D008775:Methylprednisolone